| Status | Study |
| Recruiting |
Study Name: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma Condition: Adult T-Cell Leukemia/Lymphoma Anaplastic Large Cell Lymphoma, ALK-Negative Date: 2017-04-10 Interventions: Drug: Brentuximab Vedotin Give |
| Recruiting |
Study Name: Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Condition: Blastic Plasmacytoid Dendritic Cell Neoplasm Hepatosplenic T-Cell Lymphoma Date: 2017-03-01 Interventions: Other: Laboratory Biomarker Analysis |
| Recruiting |
Study Name: Risk Stratification of Nodal PTCL Condition: Peripheral T-Cell Lymphoma, Not Otherwise Specified Angioimmunoblastic Date: 2017-01-31 |
| Recruiting |
Study Name: A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma Condition: Lymphoma Date: 2017-01-16 Interventions: Drug: plitidepsin Other Name: APLD Aplidine |
| Recruiting |
Study Name: VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma Condition: Previously Treated Myelodysplastic Syndrome Recurrent Adult Acute Myeloid Leukemia Date: 2017-01-09 Interventions: Biological: Biological Therapy |
| Recruiting |
Study Name: CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Condition: Acute Myeloid Leukemia Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Date: 2016-03-31 Interventions: Biological: anti-CD7 CAR-pNK cells The allogeneic NK cells (NK-92 cell line for clinical use) are engine |
| Recruiting |
Study Name: Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma Condition: Adult Nasal Type Extranodal NK/T-Cell Lymphoma Adult T-Cell Leukemia/Lymphoma Date: 2016-01-08 Interventions: Other: Laboratory Biomarker Analysis |
| Recruiting |
Study Name: A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) Condition: T-cell Lymphoma Angioimmunoblastic T-cell Lymphoma Date: 2015-10-26 Interventions: Drug: Brentuximab vedotin study drug given intravenously to determine efficacy in study diseases |
| Recruiting |
Study Name: Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma Condition: Anaplastic Large Cell Lymphoma, ALK-Negative Anaplastic Large Cell Lymphoma, ALK-Positive Date: 2015-09-24 Interventions: Drug: Cyclophosphamide Given I |
| Recruiting |
Study Name: Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma Condition: Follicular Variant Peripheral T-Cell Lymphoma Recurrent Angioimmunobla Date: 2015-08-10 Interventions: Biological: Anti-ICOS Monoclonal Antibody MEDI-570 |